Cargando…

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk

An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed of a skeleton of fibrin fibres with cellular e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kearney, Katherine, Tomlinson, Darren, Smith, Kerrie, Ajjan, Ramzi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345237/ https://www.ncbi.nlm.nih.gov/pubmed/28279217 http://dx.doi.org/10.1186/s12933-017-0515-9

Ejemplares similares

The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk
por: Safdar, Nawaz Z., et al.
Publicado: (2023)

Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics
por: Pechlivani, Nikoletta, et al.
Publicado: (2021)

Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis—From Pathophysiology to Therapeutic Implications
por: Badescu, Minerva Codruta, et al.
Publicado: (2022)

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target
por: Altalhi, Rawan, et al.
Publicado: (2021)

Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation
por: Bryk-Wiązania, Agata Hanna, et al.
Publicado: (2021)

Non-Traditional Pathways for Platelet Pathophysiology in Diabetes: Implications for Future Therapeutic Targets
por: Sagar, Rebecca C., et al.
Publicado: (2022)

Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
por: Pechlivani, Nikoletta, et al.
Publicado: (2018)

Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges
por: Gaule, Thembaninkosi G., et al.
Publicado: (2021)

Determinants of hypofibrinolysis in patients with digestive tract cancer
por: Gronostaj, Katarzyna, et al.
Publicado: (2016)

Development and application of global assays of hyper‐ and hypofibrinolysis
por: Ilich, Anton, et al.
Publicado: (2019)

Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019
por: Wada, Hideo, et al.
Publicado: (2023)

Increased thrombin activatable fibrinolysis inhibitor activity is associated with hypofibrinolysis in dogs with sepsis
por: Sotos, Katherine E., et al.
Publicado: (2023)

Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19
por: Schrick, Diana, et al.
Publicado: (2021)

Platelet–Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches
por: Gauer, Julia S., et al.
Publicado: (2022)

Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis
por: Meltzer, Mirjam E, et al.
Publicado: (2008)

Prevalence of genetic risk factors related with thrombophilia and hypofibrinolysis in patients with osteonecrosis of the femoral head in Poland
por: Gagala, Jacek, et al.
Publicado: (2013)

Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target
por: Alsayejh, Basmah, et al.
Publicado: (2022)

Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy
por: Jarman, Michael Ian, et al.
Publicado: (2017)

More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC
por: Zanetto, Alberto, et al.
Publicado: (2021)

PAI-1 Overexpression in Valvular Interstitial Cells Contributes to Hypofibrinolysis in Aortic Stenosis
por: Kopytek, Magdalena, et al.
Publicado: (2023)

Hypofibrinolysis in pediatric patients with veno-occlusive disease in hematopoietic stem cell transplantation
por: Schneider, Veronika, et al.
Publicado: (2023)

Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis
por: Bryk, Agata H., et al.
Publicado: (2019)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019)

Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk
por: King, Rhodri J., et al.
Publicado: (2020)

Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention: Structured intervention for community hypoglycemia
por: Pearson, Sam M., et al.
Publicado: (2021)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson, Sam, et al.
Publicado: (2019)

Strategies for Therapeutic Amelioration of Aberrant Plasma Zn(2+) Handling in Thrombotic Disease: Targeting Fatty Acid/Serum Albumin-Mediated Effects
por: Regan-Smith, Spencer, et al.
Publicado: (2022)

Prolonged Inflammatory Response Post-Hypoglycemia: Mechanistic Insights Into the Relationship Between Low Glucose and Cardiovascular Risk
por: Iqbal, Ahmed, et al.
Publicado: (2022)

Hypofibrinolysis induced by tranexamic acid does not influence inflammation and mortality in a polymicrobial sepsis model
por: Campos Nogueira, Yzabella Alves, et al.
Publicado: (2019)

Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection
por: Otamas, Anastasia, et al.
Publicado: (2020)

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction
por: Ciaccio, Marcello, et al.
Publicado: (2008)

Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial
por: Ajjan, Ramzi A, et al.
Publicado: (2019)

Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
por: Warnes, Harriet, et al.
Publicado: (2018)

Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes
por: Dixon, Stephan G, et al.
Publicado: (2016)

Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival
por: Blasi, Annabel, et al.
Publicado: (2019)

Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
por: Ajjan, Ramzi, et al.
Publicado: (2019)

Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients?
por: Zouaoui Boudjeltia, Karim, et al.
Publicado: (2004)

Tool guide for lifestyle behavior change in a cardiovascular risk reduction program
por: White, Nicole D, et al.
Publicado: (2013)

Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study
por: Brown, Oliver I., et al.
Publicado: (2023)

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_32uegvegehls1akr18m18qfnvb